Table 2 Patient Characteristics
Study and Treatment Arm | Mean Age at Enrollmenta | Patient Sexb | Total | Expected Weeks | Dexc | Doxorubicin | Trastuzumab | ||
|---|---|---|---|---|---|---|---|---|---|
Male | Female | ||||||||
AOST0121 | AOST0121 HER2 Negative | 15.1 (3.6) | 33 (60.0%) | 22 (40.0%) | 55 (100%) | 34 | 3.75 g/m2 | 375 mg/m2 | 70 mg/kg |
AOST0121 HER2 Positive | 13.7 (2.7) | 19 (47.5%) | 21 (52.5%) | 40 (100%) | 34 | 3.75 g/m2 | 375 mg/m2 | ||
P9754 | P9754 Pilot 1 Good Response | 13.5 (5.0) | 16 (47.1%) | 18 (52.9%) | 34 (100%) | 28 | 4.5 g/m2 | 450 mg/m2 | |
P9754 Pilot 1 Standard Response | 13.9 (4.4) | 48 (62.3%) | 29 (37.7%) | 77 (100%) | 29 | 6 g/m2 | 600 mg/m2 | ||
P9754 Pilot 2 Good Response | 13.9 (3.9) | 7 (33.3%) | 14 (66.7%) | 21 (100%) | 28 | 4.5 g/m2 | 450 mg/m2 | ||
P9754 Pilot 2 Standard Response | 13.8 (4.5) | 20 (60.6%) | 13 (39.4%) | 33 (100%) | 31 | 6 g/m2 | 600 mg/m2 | ||
P9754 Pilot 3 Good Response | 14.3 (4.0) | 12 (63.2%) | 7 (36.8%) | 19 (100%) | 28 | 4.5 g/m2 | 450 mg/m2 | ||
P9754 Pilot 3 Standard Response | 13.4 (4.6) | 20 (54.1%) | 17 (45.9%) | 37 (100%) | 36 | 4.5 g/m2 | 450 mg/m2 | ||